Targeted Iron-Oxide Nanoparticle for Photodynamic Therapy and Imaging of Head and Neck Cancer
Source abstract
Abstract
Photodynamic therapy (PDT) is a highly specific anticancer treatment modality for various cancers, particularly for recurrent cancers that no longer respond to conventional anticancer therapies. PDT has been under development for decades, but light-associated toxicity limits its clinical applications. To reduce the toxicity of PDT, we recently developed a targeted nanoparticle (NP) platform that combines a second-generation PDT drug, Pc 4, with a cancer targeting ligand, and iron oxide (IO) NPs. Carboxyl functionalized IO NPs were first conjugated with a fibronectin-mimetic peptide (Fmp), which binds integrin β1. Then the PDT drug Pc 4 was successfully encapsulated into the ligand-conjugated IO NPs to generate Fmp-IO-Pc 4. Our study indicated that both nontargeted IO-Pc 4 and targeted Fmp-IO-Pc 4 NPs accumulated in xenograft tumors with higher concentrations than nonformulated Pc 4. As expected, both IO-Pc 4 and Fmp-IO-Pc 4 reduced the size of HNSCC xenograft tumors more effectively than free Pc 4. Using a 10-fold lower dose of Pc 4 than that reported in the literature, the targeted Fmp-IO-Pc 4 NPs demonstrated significantly greater inhibition of tumor growth than nontargeted IO-Pc 4 NPs. These results suggest that the delivery of a PDT agent Pc 4 by IO NPs can enhance treatment efficacy and reduce PDT drug dose. The targeted IO-Pc 4 NPs have great potential to serve as both a magnetic resonance imaging (MRI) agent and PDT drug in the clinic.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, United States
Ocean NanoTech LLC, San Diego, California 92126, United States
Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, United States
References (74)
Show source-provided references
1. Siegel R. · Ca—Cancer J. Clin. · 2013 · 63 · 1110.3322/caac.21166 ↗
2. Jermal A. · Ca—Cancer J. Clin. · 2011 · 61 · 6910.3322/caac.20107 ↗
3. Molin Y. · Anticancer Drugs · 2011 · 22 · 62110.1097/CAD.0b013e3283421f7c ↗
4. Shin D. M. · Head Neck · 2013 · 35 · 44310.1002/hed.21910 ↗
5. Dolmans D. E. · Nat. Rev. Cancer · 2003 · 3 · 38010.1038/nrc1071 ↗
6. Hahn S. M. · Curr. Treat. Options Oncol. · 2001 · 2 · 37510.1007/s11864-001-0042-4 ↗
7. Oleinick N. L. · Photochem. Photobiol. Sci. · 2002 · 1 · 110.1039/b108586g ↗
8. Agostinis P. · Ca—Cancer J. Clin. · 2011 · 61 · 25010.3322/caac.20114 ↗
9. Idris N. M. · Nat. Med. · 2012 · 18 · 158010.1038/nm.2933 ↗
10. Civantos F. · J. Natl. Compr. Cancer Network · 2012 · 10 · s6510.6004/jnccn.2012.0179 ↗
11. Jerjes W. · Lasers Surg. Med. · 2011 · 43 · 46310.1002/lsm.21071 ↗
12. Biel M. A. · Methods Mol. Biol. · 2010 · 635 · 28110.1007/978-1-60761-697-9_18 ↗
13. Rigual N. R. · Arch. Otolaryngol., Head Neck Surg. · 2009 · 135 · 78410.1001/archoto.2009.98 ↗
14. He J. · Photochem. Photobiol. · 1997 · 65 · 58110.1111/j.1751-1097.1997.tb08609.x ↗
15. Baron E. D. · Lasers Surg. Med. · 2010 · 42 · 72810.1002/lsm.20962 ↗
16. Lee T. K. · J. Biomed. Opt. · 2008 · 13 · 03050710.1117/1.2939068 ↗
17. Wang H. · J. Magn. Reson. Imaging · 2010 · 32 · 40910.1002/jmri.22247 ↗
18. Fei B. · J. Nucl. Med. · 2010 · 51 · 13010.2967/jnumed.109.067579 ↗
19. Fei B. · Proc. SPIE · 2009 · 7262 · 1
20. Cheng Y. · J. Am. Chem. Soc. · 2008 · 130 · 1064310.1021/ja801631c ↗
21. Fei B. · Lasers Surg. Med. · 2007 · 39 · 72310.1002/lsm.20576 ↗
22. Fei B. · Med. Phys. · 2006 · 33 · 75310.1118/1.2163831 ↗
23. Davis E. D. · Nat. Rev. Drug Discovery · 2008 · 7 · 77210.1038/nrd2614 ↗
24. Lee S. J. · J. Nanosci. Nanotechnol. · 2011 · 11 · 705710.1166/jnn.2011.4861 ↗
25. Hayashi K. · Theranostics · 2013 · 3 · 36610.7150/thno.5860 ↗
26. Fang C. · Nanomedicine (London, U. K.) · 2010 · 5 · 135710.2217/nnm.10.55 ↗
27. He H. · Pharm. Res. · 2013 · 30 · 244510.1007/s11095-013-0982-y ↗
28. Choi H. S. · Mol. Imaging · 2010 · 9 · 291
29. Tassa C. · Acc. Chem. Res. · 2011 · 44 · 84210.1021/ar200084x ↗
30. Wu C. · J. Biol. Chem. · 1993 · 268 · 2188310.1016/S0021-9258(20)80623-1 ↗
31. Van Waes C. · Cancer Res. · 1995 · 55 · 5434
32. Eke I. · J. Clin. Invest. · 2012 · 122 · 152910.1172/JCI61350 ↗
33. Wang D. · Clin. Cancer Res. · 2012 · 18 · 458910.1158/1078-0432.CCR-11-3127 ↗
34. Mardilovich A. · Langmuir · 2006 · 22 · 325910.1021/la052756n ↗
35. Garg · Curr. Pharm. Biotechnol. · 2011 · 12 · 113510.2174/138920111796117328 ↗
36. Flors C. · J. Exp. Bot. · 2006 · 57 · 172510.1093/jxb/erj181 ↗
37. Yano T. · Int. J. Cancer · 2012 · 131 · 122810.1002/ijc.27320 ↗
38. Egorin M. J. · Cancer Chemother. Pharmacol. · 1999 · 44 · 28310.1007/s002800050979 ↗
39. Miller J. D. · Toxicol. Appl. Pharmacol. · 2007 · 224 · 29010.1016/j.taap.2007.01.025 ↗
40. Werner M. E. · ACS Nano · 2011 · 5 · 899010.1021/nn203165z ↗
41. Master A. M. · Nanomedicine · 2012 · 8 · 65510.1016/j.nano.2011.09.012 ↗
42. Li P. · Oncol. Rep. · 2010 · 24 · 988
43. Atchison N. A. · Langmuir · 2010 · 26 · 1408110.1021/la101264h ↗
44. Pangburn T. O. · Langmuir · 2012 · 28 · 1281610.1021/la300874z ↗
45. Beech J. R. · Curr. Pharm. Des. · 2013 · 19 · 656010.2174/1381612811319370002 ↗
46. Singh S. · Cancer Res. · 2012 · 72 · 566310.1158/0008-5472.CAN-12-1527 ↗
47. Xu S. · Adv. Drug Delivery Rev. · 2013 · 65 · 12110.1016/j.addr.2012.09.041 ↗
48. Master A. M. · Mol. Pharm. · 2012 · 9 · 233110.1021/mp300256e ↗
49. Master A. · Mol. Pharm. · 2013 · 10 · 198810.1021/mp400007k ↗
50. Mir Y. · Nanomedicine · 2013 · 9 · 111410.1016/j.nano.2013.02.005 ↗
51. Li W. · J. Mater. Chem. · 2012 · 22 · 1270110.1039/c2jm30897e ↗
52. Bao G. · Annu. Rev. Biomed. Eng. · 2013 · 15 · 25310.1146/annurev-bioeng-071812-152409 ↗
53. Le Duc G. · ACS Nano · 2011 · 5 · 956610.1021/nn202797h ↗
54. Yu M. K. · Small · 2011 · 7 · 224110.1002/smll.201100472 ↗
55. Pouliquen D. · Magn. Reson. Imaging · 1989 · 7 · 61910.1016/0730-725X(89)90530-4 ↗
56. Kumar M. · Cancer Res. · 2010 · 70 · 755310.1158/0008-5472.CAN-10-2070 ↗
57. Ling D. · Small · 2013 · 9 · 145010.1002/smll.201202111 ↗
58. Sjogren C. E. · Magn. Reson. Imaging · 1997 · 15 · 5510.1016/S0730-725X(96)00335-9 ↗
59. Wunderbaldinger P. · Magn. Reson. Med. · 2002 · 47 · 29210.1002/mrm.10068 ↗
60. Hogemann D. · Bioconjugate Chem. · 2000 · 11 · 94110.1021/bc000079x ↗
61. Bulte J. W. · NMR Biomed. · 2004 · 17 · 48410.1002/nbm.924 ↗
62. Moore A. · J. Magn. Reson. Imaging · 1997 · 7 · 114010.1002/jmri.1880070629 ↗
63. Schultz J. F. · Ann. Surg. Oncol. · 1999 · 6 · 69110.1007/s10434-999-0691-2 ↗
64. Harisinghani M. G. · N. Engl. J. Med. · 2003 · 348 · 249110.1056/NEJMoa022749 ↗
65. Kircher M. F. · Cancer Res. · 2003 · 63 · 6838
66. Lewin M. · Nat. Biotechnol. · 2000 · 18 · 41010.1038/74464 ↗
67. Tang M. F. · Chin. J. Cancer · 2010 · 29 · 77510.5732/cjc.010.10075 ↗
68. Yamashita K. · Cytokine · 2009 · 48 · 5510.1016/j.cyto.2009.07.164 ↗
69. Buyukhatipoglu K. · J. Biomed. Mater. Res., Part A · 2011 · 96 · 18610.1002/jbm.a.32972 ↗
70. Gilli G. · Environ. Toxicol. Pharmacol. · 2008 · 25 · 8910.1016/j.etap.2007.09.004 ↗
71. Higai K. · Biochim. Biophys. Acta · 2008 · 1780 · 30710.1016/j.bbagen.2007.11.010 ↗
72. Katavetin P. · Biochem. Biophys. Res. Commun. · 2008 · 367 · 30510.1016/j.bbrc.2007.12.086 ↗
73. Yokoe J. · Int. J. Pharm. · 2008 · 353 · 2810.1016/j.ijpharm.2007.11.008 ↗
74. Wang D. · Mol. Cancer · 2011 · 10 · 11610.1186/1476-4598-10-116 ↗